EUVIMEDEUVIMED entdecken
Crossref

Structure‐based Virtual Screening and Drug Design Development of Leishmanicidal Pyrimidines

Gerliny Bezerra de Oliveira, Érick Caique Santos Costa, Zenaide Severina do Monte, Gleybson Correia de Almeida, Emerson Peter da Silva Falcão, Luciana Scotti, Marcus Tullius Scotti, Ricardo Oliveira Silva, Daniele Santana de Sousa Oliveira, Policarpo Ademar Sales Junior, Valéria Rêgo Alves Pereira, Sebastião José de Melo iD

Chemistry & Biodiversity · 2025

DOI: 10.1002/cbdv.202402881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Gerliny Bezerra de Oliveira und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco/UFPE, Recife, Brazil. Hauptthemen laut MEDLINE: Pyrimidines, Drug Design, Leishmania, Antiprotozoal Agents. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leishmaniasis is a neglected disease caused by parasites of the genus Leishmania sp . that causes approximately 1 million cases and 650,000 deaths annually worldwide. Its treatment has several limitations mainly due to high toxicity and clinical resistance, and the search for alternatives is highly desirable. The present work aimed to design new antileishmanial compounds through a virtual screening of a small in‐house library of pyrimidine compounds, never tested against Leishmania , using the active site of trypanothione reductase (TR) as a target model. The compounds showed favorable affinity with the amino acid residues of the active site of TR. Pyr 1–9 were synthesized and tested against Leishmania amazonensis strain. Four derivatives demonstrated activity against promastigote (IC 50 value between 11.23 and 91.5 µM) and three other compounds demonstrated discreet activity against amastigote, IC 50 value between 81.29 and 153.21 µM. Based on the results obtained in the screening, three new pyrimidines Pyr 10–12 were designed to optimize activity, cytotoxicity, and selectivity. Pyr 10 and Pyr 11 demonstrated good activity against promastigotes, with IC 50 of 11.38 ± 9.7 and 20.01 ± 13.55 µM, respectively, and improved cytotoxicity and selectivity. No activity was obtained against amastigotes. Thus, this study contributes important information for the development of new pyrimidines active against Leishmania .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesDrug DesignLeishmaniaAntiprotozoal AgentsStructure-Activity RelationshipParasitic Sensitivity TestsMolecular StructureDose-Response Relationship, DrugDrug Evaluation, PreclinicalNADH, NADPH OxidoreductasesAnimalsMolecular Docking SimulationHumans

Stichwörter der Autor:innen

antileishmanial | pyrimidine derivatives | structure‐based drug design | struct…

Substanzen

PyrimidinesAntiprotozoal Agentstrypanothione reductaseNADH, NADPH Oxidoreductases

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco/UFPE, Recife, Brazil.
  • Department of Biosciences, Postgraduate Program in Biological Sciences, Federal University of Pernambuco/UFPE, Recife, Brazil.
  • Nutrition Department, Vitória Academic Center, Federal University of Pernambuco, Vitoria de Santo Antao, Brazil.
  • Department of Chemistry, Health Sciences Center, Laboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products (PgPNSB), Federal University of Paraiba, Joao Pessoa, Brazil.
  • Federal University of Pernambuco, Recife, Brazil.
  • Department of Immunology, Aggeu Magalhães Research Center, Oswaldo Cruz Foundation, Federal University of Pernambuco, Recife, Brazil.

ORCID-Profile: Sebastião José de Melo

Zitieren

APA

de Oliveira, G. B., Santos Costa, É. C., Severina do Monte, Z., de Almeida, G. C., da Silva Falcão, E. P., Scotti, L., Tullius Scotti, M., Oliveira Silva, R., de Sousa Oliveira, D. S., Ademar Sales Junior, P., Alves Pereira, V. R., & José de Melo, S. (2025). Structure‐based Virtual Screening and Drug Design Development of Leishmanicidal Pyrimidines. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202402881

Vancouver

de Oliveira GB, Santos Costa ÉC, Severina do Monte Z, de Almeida GC, da Silva Falcão EP, Scotti L, et al. Structure‐based Virtual Screening and Drug Design Development of Leishmanicidal Pyrimidines. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202402881

BibTeX
@article{deOliveira2025,
  author = {de Oliveira, Gerliny Bezerra and Santos Costa, Érick Caique and Severina do Monte, Zenaide and de Almeida, Gleybson Correia and da Silva Falcão, Emerson Peter and Scotti, Luciana and Tullius Scotti, Marcus and Oliveira Silva, Ricardo and de Sousa Oliveira, Daniele Santana and Ademar Sales Junior, Policarpo and Alves Pereira, Valéria Rêgo and José de Melo, Sebastião},
  title = {Structure‐based Virtual Screening and Drug Design Development of Leishmanicidal Pyrimidines},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  doi = {10.1002/cbdv.202402881}
}
Kostenlos starten →